Plain-English translation of NCT05191381 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is investigating whether stem cell-derived exosomes—tiny particles from specialized cells that have anti-inflammatory properties—can help reduce the severe inflammation and lung damage that occurs in critically ill COVID-19 patients. Researchers believe these particles may calm the immune system's overreaction and help the lungs heal. The study will test whether this approach can help patients who have developed severe lung failure requiring special breathing support.
Some COVID-19 patients develop life-threatening lung damage caused by their immune system overreacting and attacking their own lungs. Standard treatments don't always work for these critically ill patients. This trial exists to see if the medication can harness the healing properties of stem cells to reduce this dangerous inflammation and support lung repair.
You likely qualify if…
You likely don't qualify if…
The study will involve receiving the stem cell-derived exosome treatment as part of your care for severe COVID-19. Researchers will also conduct blood tests to measure how your immune system responds and whether inflammation decreases. The exact number of visits and duration of the study will depend on your clinical condition, but the focus is on understanding whether this treatment helps reduce the life-threatening inflammation that occurs in your lungs.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
Germany
Sponsor
University of Ulm
Enrollment target
~40 participants
Started
December 2021
Primary completion
July 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 90 Years
Last updated on clinicaltrials.gov in January 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Manfred Weiss, MD
Clinic of Anaesthesiology and Intensive Care Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.